Cellular Biomedicine: ECC 2015 (Cellular Biomedicine Group) - Nov 5, 2015 - “Adoptive CART immune cell transfer protocol targeting Her-1 is safe, feasible and effective for Her-1 positive advanced relapsed/refractory NSCLC patients”
P1 data • Non Small Cell Lung Cancer • Oncology
|